Handling Missing Data in Clinical Trials: An Overview

被引:0
|
作者
William R. Myers
机构
[1] Procter and Gamble Pharmaceuticals,Department of Biometrics and Statistical Sciences
[2] Procter and Gamble Pharmaceuticals,Department of Biometrics and Statistical Sciences
来源
Drug information journal : DIJ / Drug Information Association | 2000年 / 34卷 / 2期
关键词
Clinical trials; Missing data; Dropouts; Imputation methods; Missing-data mechanism;
D O I
暂无
中图分类号
学科分类号
摘要
A major problem in the analysis of clinical trials is missing data caused by patients dropping out of the study before completion. This problem can result in biased treatment comparisons and also impact the overall statistical power of the study. This paper discusses some basic issues about missing data as well as potential “watch outs.” The topic of missing data is often not a major concern until it is time for data collection and data analysis. This paper provides potential design considerations that should be considered in order to mitigate patients from dropping out of a clinical study. In addition, the concept of the missing-data mechanism is discussed. Five general strategies of handling missing data are presented: I. Complete-case analysis, 2. “Weighting methods,” 3. Imputation methods, 4. Analyzing data as incomplete, and 5. “Other” methods. Within each strategy, several methods are presented along with advantages and disadvantages. Also briefly discussed is how the International Conference on Harmonization (ICH) addresses the issue of missing data. Finally, several of the methods that are illustrated in the paper are compared using a simulated data set.
引用
收藏
页码:525 / 533
页数:8
相关论文
共 50 条
  • [31] A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes
    Ibrahim, Fowzia
    Tom, Brian D. M.
    Scott, David L.
    Prevost, Andrew Toby
    TRIALS, 2016, 17
  • [32] The design and conduct of clinical trials to limit missing data
    Little, R. J.
    Cohen, M. L.
    Dickersin, K.
    Emerson, S. S.
    Farrar, J. T.
    Neaton, J. D.
    Shih, W.
    Siegel, J. P.
    Stern, H.
    STATISTICS IN MEDICINE, 2012, 31 (28) : 3433 - 3443
  • [33] A structured framework for assessing sensitivity to missing data assumptions in longitudinal clinical trials
    Mallinckrod, C. H.
    Lin, Q.
    Molenberghs, M.
    PHARMACEUTICAL STATISTICS, 2013, 12 (01) : 1 - 6
  • [34] Missing data methods in HIV clinical trials: Regulatory guidance and alternative approaches
    Kelleher, T
    Thiry, A
    Wilber, R
    Cross, A
    DRUG INFORMATION JOURNAL, 2001, 35 (04): : 1363 - 1371
  • [35] When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts
    Jakobsen, Janus Christian
    Gluud, Christian
    Wetterslev, Jorn
    Winkel, Per
    BMC MEDICAL RESEARCH METHODOLOGY, 2017, 17
  • [36] Conservative handling of missing data
    Berger, Vance W.
    CONTEMPORARY CLINICAL TRIALS, 2012, 33 (03) : 460 - 460
  • [37] The prevention and handling of the missing data
    Kang, Hyun
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2013, 64 (05) : 402 - 406
  • [38] Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches
    Thomas Kelleher
    Alexandra Thiry
    Richard Wilber
    Anne Cross
    Drug information journal : DIJ / Drug Information Association, 2001, 35 : 1363 - 1371
  • [39] A hybrid approach of handling missing data under different missing data mechanisms: VISIBLE 1 and VARSITY trials for ulcerative colitis
    Chen, Jingjing
    Hunter, Sharon
    Kisfalvi, Krisztina
    Lirio, Richard A.
    CONTEMPORARY CLINICAL TRIALS, 2021, 100
  • [40] When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
    Janus Christian Jakobsen
    Christian Gluud
    Jørn Wetterslev
    Per Winkel
    BMC Medical Research Methodology, 17